

## NON-GISP REPORTING OF RESISTANCE

The Association of Public Health Laboratories and STD project areas were informally surveyed in 2000-2001 to identify cities or states that routinely performed antimicrobial susceptibility testing of *N. gonorrhoeae* in 2000. Information was not available on 16 of the 65 STD project areas. In 2000, no testing outside GISP occurred in Alabama, Arkansas, Arizona, Baltimore, Chicago, Colorado, Connecticut, Delaware, Idaho, Illinois, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Missouri, Nevada, New Mexico, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Rhode Island, San Francisco, South Carolina, Tennessee, Vermont, Washington, D.C., Washington, or Wyoming. Information on testing in 2000 was available for 17 areas (**Table 1**).

**Table 1.** Non-GISP antimicrobial susceptibility testing of *N. gonorrhoeae* in 17 STD project areas in 2000.

Project Area	Total # Isolates	Cip S	Cip I	Cip R	Spc S	Spc R	Cfx S	Cfx DS	Cro S	Cro DS	Azi S	Azi DS <sup>a</sup>
CA												
San Diego	11	11 <sup>b</sup>	0	0	-	-	-	-	11	0	-	-
Santa Ana	11	11	0	0	11	0	11	0	11	0	10	1
FL	46	46	0	0	-	-	-	-	46	0	-	-
GA	534	534 <sup>b</sup>	0	0	534	0	-	-	534	0	-	-
HI	159	140	2	17	83	0	70	0	83	0	70	0
Los Angeles	1	1	0	0	-	-	-	-	1	0	-	-
MA	323	322	0	1	5	0	-	-	322	1	-	-
MI	225	224 <sup>b</sup>	0	0	-	-	224	0	225	0	-	-
MN	255	253	2	0	255	0	255	0	255	0	-	-
MS	1282	1282	0	0	-	-	-	-	61	0	-	-
MT	4	-	-	-	4	0	-	-	4	0	-	-
NH	17	17	0	0	17	0	-	-	17	0	-	-
NJ	253	253	0	0	253	0	253	0	253	0	-	-
NY												
Buffalo	77	75	1	1	77	0	74	3	75	2	-	-
NYC	2092	2086 <sup>b</sup>	2	4	1251	0	-	-	2092	0	-	-
TX	84	84	0	0	-	-	-	-	84	0	-	-
UT	93	93 <sup>b</sup>	0	0	-	-	-	-	93	0	-	-
VA	15	15	0	0	15	0	-	-	15	0	-	-
WI												
Milwaukee	203	198	4	1	-	-	-	-	203	0	-	-
Total	5685	5645	11	24	2505	0	887	3	4385	3	80	1

Cip=ciprofloxacin; Spc=spectinomycin; Cfx=cefixime; Cro=ceftriaxone; Azi=azithromycin; S=susceptible; DS=decreased susceptibility; I=intermediate resistant; R=resistant.

The testing methodology for all sites except Texas and Florida was by disk diffusion; Texas and Florida used the E-test method.

<sup>a</sup>For this table, AziDS is defined as an isolate with azithromycin disk inhibition zone size  $\leq 35$ mm.

<sup>b</sup>Georgia, Michigan, Utah, and San Diego, California tested all isolates against ofloxacin, rather than against ciprofloxacin. New York City tested isolates against ciprofloxacin from January until July 2000 and against ofloxacin from August until December 2000.

### Acknowledgements

For their assistance in gathering these susceptibility data, we acknowledge and thank: San Diego, California - Gerry Washabaugh; Santa Ana, California - Paul Hannah and Karen Galliher; Florida - Susanne Crowe and Ron Baker; Georgia - Marsha Ray; Hawaii - Norman O'Connor; Los Angeles, California - Deborah Brown and Leonard Lawani;

Massachusetts - Al Foley; Michigan - Frances Pouch Downes and Aloysius Hanson; Minnesota - Sue Johnson and John Hunt; Mississippi - Degin Booker; Montana - Susanne Zanto; New Hampshire - Daniel Hubbard and Peggy Sweeney; New Jersey - Keith Pilot; Buffalo, New York - Scott Zimmerman and Linda Garringer; New York City, New York - George Williams, Aziz Toma, and Gladys Schlanger; Texas - Bruce Elliott and Tamara Baldwin; Utah - Kim Christensen; Virginia - Thomas York and Judith Carroll; Milwaukee, Wisconsin - Ajaib Singh.